Rationale and Design of two Phase 3 Randomized Controlled Trials (Evolution RMS 1&2) Evaluating the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib in Patients with Relapsing Multiple Sclerosis (4071)

Montalbán, Xavier; Arnold, Douglas L.; Bar‐Or, Amit; Cross, Anne H.; Havrdová, Eva; Stüve, Olaf; Weber, Martin S.; Wiendl, Heinz; Wolinsky, Jerry S.; Syed, Sana

doi:10.1212/wnl.94.15_supplement.4071

Rationale and Design of two Phase 3 Randomized Controlled Trials (Evolution RMS 1&2) Evaluating the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib in Patients with Relapsing Multiple Sclerosis (4071)

NobleIDNI2P28W82R82S76

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/5DFBA0BD.svg?ark=w1%2F20260521%2F5DFBA0BD&value=id)](https://nobleid.org/work/w1/20260521/5DFBA0BD)

ARK Inflections

Metadata (JSON)Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Rationale and Design of two Phase 3 Randomized Controlled Trials (Evolution RMS 1&2) Evaluating the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib in Patients with Relapsing Multiple Sclerosis (4071)

NobleIDNI2P28W82R82S76

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/5DFBA0BD.svg?ark=w1%2F20260521%2F5DFBA0BD&value=id)](https://nobleid.org/work/w1/20260521/5DFBA0BD)

ARK Inflections

Metadata (JSON)Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work